Alpha Centric Advisors LLC Aldeyra Therapeutics, Inc. Transaction History
Alpha Centric Advisors LLC
- $97.4 Million
- Q4 2024
A detailed history of Alpha Centric Advisors LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 46,913 shares of ALDX stock, worth $258,021. This represents 0.24% of its overall portfolio holdings.
Number of Shares
46,913Holding current value
$258,021% of portfolio
0.24%Shares
1 transactions
Others Institutions Holding ALDX
# of Institutions
132Shares Held
34.9MCall Options Held
244KPut Options Held
51.6K-
Knoll Capital Management, LLC Miami, FL5.48MShares$30.1 Million14.27% of portfolio
-
Perceptive Advisors LLC New York, NY4.05MShares$22.3 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$19.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.5MShares$19.3 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT2.05MShares$11.3 Million1.29% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $321M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...